| |
All patients |
|
| |
N |
% |
| Patients enrolled |
119 |
|
|
Age, years |
51
68
53.5
52 |
42.9
57.1 |
≤ 50
> 50
Mean
Median |
| Tumor type
|
100
4
3
3
10 |
83.3
3.3
2.5
2.4
8.5 |
IDC
ILC
IDC+ILC
Others
Not reported |
| Tumor size, cm |
33
50
24
12 |
27.7
42.0
20.2
10.1 |
0-1.9
2-3.9
≥ 4
Not reported |
| Tumor grade
|
5
49
2
45
12 |
4.2
40.8
1.7
37.5
10 |
1
2
2-3
3
Not reported |
| Metastatic size, mm
|
52
0
2
65 |
43.7
0
1.7
54.6 |
0
< 0.2
0.2-2
> 2 |
| Angiolyphatic invasion
|
39
54
26 |
32.8
45.4
21.8 |
Involved
Not involved
Not reported |
| Perineural invasion
|
16
57
46 |
13.4
47.9
38.7 |
Involved
Not involved
Not reported |
| Nipple/Skin involvement
|
4
77
38 |
3.4
64.7
31.9 |
Involved
Not involved
Not reported |
| Resection margin
|
41
67
11 |
34.5
56.3
9.2 |
Free
Not free
Not reported |
| Estrogen receptor
|
68
38
13 |
57.1
34.5
9.2 |
Positive
Negative
Not reported |
| Progesterone receptor
|
61
45
13 |
51.3
37.8
10.9 |
Positive
Negative
Not reported |
| HER2/neu
|
31
22
31
21
14 |
26.1
18.5
26.1
17.6
11.8 |
1+
2+
3+
Negative
Not reported |
